leadf
logo-loader
OTCQB:BETRF CSE:BETR

BetterLife Pharma Inc

Receive alerts
Market:
OTCQB
Market Cap:
$13.3 m
Price
0.73 USD
Change
-11.29%
52 weeks high
2.21
52 weeks low
0.10

In brief

BLife Therapeutics, a wholly-owned subsidiary of BetterLife Pharma Inc., is focused on the development of its patent pending Interferon formula, AP-003, for the treatment and prevention of severe COVID-19 disease. It’s parent, Better Life Pharma Inc. is an emerging biotechnology company engaged in the development and commercialization of Interferon therapeutics to meet unmet needs for patients worldwide with a pipeline of HPV-cervical dysplasia (AP-001) which has completed Phase 2 and AP-002, an oral gallium-based novel small molecule, US IND approved and has started Phase 1-2 in October 2019 in the US in cancer patients with advanced or recurrent solid tumours.

Insight Widest with the analysis, Proactive gives perspectives that others don't.

BetterLife Pharma on promising path with Altum merger and Phase 2 trial of AP-003 drug to fight coronavirus

The group’s CEO Ahmad Doroudian expects the AP-003 Phase 2 trial to be completed in the next three-to-six months, and approved under emergency use authorization

on 07/15/2020